Skip to Content

Protox To Present Interim Prostate Cancer Data at AUA Conference

VANCOUVER, British Columbia, Sept. 6, 2007 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today  announced that interim data from the recently completed Phase 1 clinical study  testing PRX302 in patients with locally recurrent prostate cancer following  radiation failure will be presented at the American Urological Association  ("AUA") South Central Section Annual Meeting. The conference will take place at the Broadmoor Hotel in Colarado Springs, Colorado.      

Scott Coffield, M.D., Principal Investigator from the lead site at Scott  and White Memorial Hospital, will present the data on Friday, September 7,  2007. The presentation, entitled "Interim Results of a Phase 1 Clinical Study  for the Transperineal Intraprostatic Administration of PRX302 (PSA-PAH1) in  Patients with Locally Recurrent Prostate Cancer" indicates that PRX302 is safe  and well tolerated in patients and that it shows encouraging signs of  therapeutic activity.      

PRX302 is rationally designed to kill prostate cancer and hyperplastic  cells that over-produce the enzyme prostate specific antigen (PSA). Patient  enrollment has been completed for this Phase 1 study and top-line results were  released in July indicating that PRX302 is safe and well tolerated and that a  maximum tolerated dose was not reached in the study while encouraging signs of  therapeutic activity were observed. Plans are currently underway to commence a  Phase 2 study before the end of the year.   

About Protox   

Protox Therapeutics is a leader in advancing novel, targeted protein  toxin therapeutics for the treatment of cancer and other proliferative  diseases. The company is actively developing two distinct but complementary  platforms, INxin(TM) and PORxin(TM), and currently has four clinical programs  in development. A Phase 2a clinical trial into the use of PRX321 (INxin) for  the treatment of primary brain cancer has been completed and the drug has  received Fast Track Designation and Orphan Drug Status from the US FDA. In  addition, a Phase 1 trial has been completed for PRX321 to treat patients with  renal cell carcinoma and non-small cell lung cancer. Patient enrollment has  been completed for a Phase 1 clinical trial into the use of PRX302 (PORxin)  for the treatment of localized prostate cancer. A Phase 1 clinical study of  PRX302 for the treatment of benign prostatic hyperplasia (enlarged prostate)  is ongoing.   


Certain statements included in this press release may be considered  forward-looking. Such statements involve known and unknown risks,  uncertainties and other factors that may cause actual results, performance or  achievements to be materially different from those implied by such statements,  and therefore these statements should not be read as guarantees of future  performance or results. All forward-looking statements are based on Protox'  current beliefs as well as assumptions made by and information currently  available to Protox and relate to, among other things, anticipated financial  performance, business prospects, strategies, regulatory developments, market  acceptance and future commitments. Readers are cautioned not to place undue  reliance on these forward-looking statements, which speak only as of the date  of this press release. Due to risks and uncertainties, including the risks and  uncertainties identified by Protox in its public securities filings; actual  events may differ materially from current expectations. Protox disclaims any  intention or obligation to update or revise any forward-looking statements,  whether as a result of new information, future events or otherwise.   

For further information: James Beesley, Director, Investor Relations,  Protox Therapeutics, (604) 688-0199,; Michael  Moore, Investor Relations, Equicom Group, (416) 815-0700 x 241,



Posted: September 2007